CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 90 enrolled
Drug / intervention
Allantoin/ Coal Tar/ Clioquinol +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05105139
NCT05105139N/ACompleted
CompareCT.gov

Retrospective Study to Evaluate the Safety of Sebryl® and / or Sebryl Plus® in the Treatment of Seborrheic Dermatitis and Psoriasis of the Scalp in Routine Medical Practice.

Laboratorios Silanes S.A. de C.V.·observational·Posted Nov 3, 2021·Updated Apr 13, 2022

In Brief

An observational study evaluating Allantoin/ Coal Tar/ Clioquinol and Allantoin/ Coal Tar/ Clioquinol/ Triclosan for Seborrheic Dermatitis and Psoriasis of Scalp. Completed, enrolled 90 participants across 1 site.

Detailed Summary

Observational, descriptive, retrospective, multicenter study to evaluate the safety of the treatment with Sebryl® and / or Sebryl Plus® in the management of seborrheic dermatitis and psoriasis of the scalp in routine medical practice.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSeborrheic Dermatitis, Psoriasis of Scalp
CountriesMexico
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedNov 3, 2021
Enrollment StartNov 29, 2021
Primary CompletionFeb 15, 2022
Study CompletionFeb 25, 2022
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 4.7 years ago

Interventions

Allantoin/ Coal Tar/ Clioquinolother

Pharmaceutical Form: Shampoo Dosage: Allantoin 0.2 g/ Coal Tar 5.0 g/ Clioquinol 3.0 g Administration way: For scalp use

Allantoin/ Coal Tar/ Clioquinol/ Triclosanother

Pharmaceutical Form: Shampoo Dosage: Allantoin 0.2 g/ Coal Tar 3.0 g/ Clioquinol 3.0 g/ Triclosan 0.3 g. Administration way: For scalp us